• Aucun résultat trouvé

Sexual consequences of prostate cancer treatment.

N/A
N/A
Protected

Academic year: 2022

Partager "Sexual consequences of prostate cancer treatment."

Copied!
1
0
0

Texte intégral

(1)

1472

Canadian Family Physician • Le Médecin de famille canadien

d VOL 5: NOVEMBER • NOVEMBRE 2005

Letters Correspondance

8. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the pri- mary prevention of cardiovascular disease and cancer: the Women’s Health Study: a random- ized controlled trial. JAMA 2005;294:56-65.

9. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med 2004;164:1552-6.

10. Vivekananthan DP, Pen MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23.

11. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analy- sis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.

12. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.

13. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Eff ect of homocysteine-lowering therapy with folic acid, vitamin B12 and vitamin B6 on clinical outcomes after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288:973-9.

14. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81.

15. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.

16. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ.

Secondary prevention with folic acid: eff ects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.

Sexual consequences of prostate cancer treatment

Y our July 2005 issue seems mislabelled. Th ere are indeed sexual consequences of advanced and aggressive prostate cancer, but the tragedy is that the

largest part of the epidemic of male sexual depreda- tion is a result of treatment, not disease.

Your issue would better be titled “Severe Sexual Consequences of Aggressive Treatment of Prostate Cancer.”

Off ering editorial comment

1

from a urologist is like inviting a logger to discuss the preservation of old-growth forests. Th e surgeon advises family physicians to explain to patients that they “might experience changes in ejaculation.”

Might? What truthful family physicians will tell their patients is, “Th is means the end of sex as you know it for almost all men treated. And by the way, as many as four in 10 of you will end up wearing a diaper at least some of the time.”

Th en, truthful family physicians will make sure their patients understand that aggressive screening and treatment of prostate cancer might, at best, prolong their lives a few months. (See Tom Pickles’s review of the lack of proven benefi t with current therapies.

2

)

Surely avoiding prostate-specifi c antigen screen- ing in asymptomatic patients and restricting surgi- cal and radiation interventions to clinically obvious cancers is the plan family physicians providing evidence-based care should follow.

—John B. Hoehn, MD, CCFP Walla Walla, Wash by mail References

1. Pommerville PJ. From bedside to bed. Recovery of sexual function after prostate cancer [editorial]. Can Fam Physician 2005;51:941-3 [Eng], 948-50 [Fr].

2. Pickles T. Current status of PSA screening. Early detection of prostate cancer. Can Fam Physician 2004;50:57-63.

Make your views known!

Contact us by e-mail at letters.editor@cfpc.ca on the College’s website at www.cfpc.ca

by fax to the Scientifi c Editor at (905) 629-0893 or by mail to Canadian Family Physician

College of Family Physicians of Canada

2630 Skymark Avenue, Mississauga, ON L4W 5A4

Faites-vous entendre!

Communiquez avec nous par courriel:

letters.editor@cfpc.ca au site web du Collège: www.cfpc.ca par télécopieur au Rédacteur scientifi que

(905) 629-0893 ou par la poste Le Médecin de famille canadien Collège des médecins de famille du Canada

2630 avenue Skymark, Mississauga, ON L4W 5A4

FOR PRESCRIBING INFORMATION SEE PAGE 1546

Références

Documents relatifs

Objective We aimed to evaluate the characteristics and clinical outcomes of patients who received their first treatment for metastatic castration-resistant prostate cancer (mCRPC)

Promoting preparation and development of realistic expectations, along with persistence, communication, flexibility, actively addressing grief, adjusting goals, and

T he purpose of this article is to describe the treatment options available for men with early stage prostate cancer: radical prostatectomy (RP), prostate brachy- therapy

OBJECTIVE To highlight the role of psychosocial variables in treat- ment decision making for patients with localized prostate cancer and how family physicians can be of most help

OBJECTIVE To describe the sexual consequences of prostate cancer and its treatments (prostatectomy, external beam radiation, brachytherapy, androgen deprivation therapy) and to

Now is not the time to screen.” 7 It should be noted that this screening test (fecal occult blood testing) does carr y with it a greater amount of evidence of benefit in terms

a qualitative, longitudinal study of prostate cancer patients and their spouses; and a sur vey of Canadian family physicians about prostate cancer issues (conducted in partnership

Data from the European Randomised Study of Screening for Prostate Cancer (ERSPC) are used here to show the balance between the potential risks and benefits associated with the